Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Sangamo Therapeutics Inc (NASDAQ: SGMO) was $0.46 for the day, down -5.33% from the previous closing price of $0.48. In other words, the price has decreased by -$5.33 from its previous closing price. On the day, 8.35 million shares were traded. SGMO stock price reached its highest trading level at $0.4643 during the session, while it also had its lowest trading level at $0.42.
Ratios:
Our analysis of SGMO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.05. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 112124176 and an Enterprise Value of 122968064. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.69 while its Price-to-Book (P/B) ratio in mrq is 6.36. Its current Enterprise Value per Revenue stands at 1.505 whereas that against EBITDA is -2.237.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.22, which has changed by -0.5818182 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is -11.08%, while the 200-Day Moving Average is calculated to be -58.45%.
Shares Statistics:
SGMO traded an average of 5.66M shares per day over the past three months and 6929210 shares per day over the past ten days. A total of 272.80M shares are outstanding, with a floating share count of 237.62M. Insiders hold about 3.17% of the company’s shares, while institutions hold 22.05% stake in the company. Shares short for SGMO as of 1752537600 were 23364456 with a Short Ratio of 4.13, compared to 1749772800 on 25671043. Therefore, it implies a Short% of Shares Outstanding of 23364456 and a Short% of Float of 9.62.
Earnings Estimates
The current rating of Sangamo Therapeutics Inc (SGMO) reflects the combined expertise of 2 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.07 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.37 and -$0.42 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $13M to a low estimate of $4M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $49.41MFor the next quarter, 4 analysts are estimating revenue of $16.48M. There is a high estimate of $35M for the next quarter, whereas the lowest estimate is $5M.
A total of 2 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $53.7M, while the lowest revenue estimate was $38.7M, resulting in an average revenue estimate of $46.2M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $50.02M in the next fiscal year. The high estimate is $114.2M and the low estimate is $9.9M.
